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Abstract Insulin-like growth factor binding proteins
(IGFBPs) are key regulators of insulin-like growth factor
(IGF) mediated signal transduction and thereby can
profoundly influence cellular phenotypes and cell fate.
Whereas IGFBPs are extracellular proteins, intracellular
activities were described for several IGFBP family mem-
bers, such as IGFBP-3, which can be reinternalized by
endocytosis and reaches the nucleus through routes that
remain to be fully established. Within the family of
IGFBPs, IGFBP-6 is unique for its specific binding to
IGF-II. IGFBP-6 was described to possess additional IGF-
independent activities, which have in part been attributed to
its translocation to the nucleus; however, cellular uptake of
IGFBP-6 was not described. To further explore IGFBP-6
functions, we developed a new method for the purification
of native human IGFBP-6 from cell culture supernatants,
involving a four-step affinity purification procedure, which
yields highly enriched IGFBP-6. Whereas protein purified
in this way retained the capacity to interact with IGF-II and
modulate IGF-dependent signal transduction, our data
suggest that, unlike IGFBP-3, human IGFBP-6 is not
readily internalized by human tumor cells. To summarize,
this work describes a novel and efficient method for the
purification of native human insulin-like growth factor
binding protein 6 (IGFBP-6) from human cell culture
supernatants, applying a four-step chromatography
procedure. Intactness of purified IGFBP-6 was confirmed
by IGF ligand Western blot and ability to modulate IGF-
dependent signal transduction. Cellular uptake studies
were performed to further characterize the purified
protein, showing no short-term uptake of IGFBP-6, in
contrast to IGFBP-3.
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Abbreviations
HDF Human diploid fibroblast
HIC Hydrophobic interaction chromatography
IGF Insulin-like growth factor
IGFBP Insulin-like growth factor binding protein
MW Molecular weight
Introduction
Insulin-like growth factor binding proteins (IGFBPs) and
the CCN (Cyr61, CTGF and Nov) proteins form two
related extracellular protein families that share a similar
amino terminal domain (Kim et al. 1997). While the main
function of IGFBPs is to modulate the action and biological
availability of IGFs (Firth and Baxter 2002), CCNs show a
weaker affinity to IGFs and are mostly known for their IGF-
independent functions (Holbourn et al. 2008). Both protein
families were linked to processes like cell growth, apoptosis,
cell migration, carcinogenesis, and aging (Baxter 2000;
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differentially regulated in a tissue-dependent fashion (Cerro
et al. 1993), suggesting that each IGFBP exerts a specific
role. IGFBP-6 stands out due to its preferential binding to
IGF-II (Martin et al. 1990), and was shown to inhibit the
growth of tumors that are dependent on IGF-II signalling
(Gallicchio et al. 2001; Grellier et al. 1998; Kim et al. 2002;
Kuo et al. 2010; Sueoka et al. 2000). Several transcription
factors such as Gli1 (Xu et al. 2009) were shown to regulate
IGFBP-6 expression (Dailly et al. 2001).
For some of the best studied IGF binding proteins, in
particular IGFBP-3 and IGFBP-5, additional functions have
been described which are not mediated by their ability to
sequester IGFs, as best demonstrated by the use of IGF
non-binding mutants (Hong et al. 2002). In the case of
IGFBP-3, IGF-independent actions seem to require intra-
cellular IGFBP-3, which can be re-internalized by endocy-
tosis. In addition, both IGFBP-3 and −5 contain functional
nuclear localization sites and both proteins can be imported to
the nucleus by an importin-dependent pathway (Schedlich et
al. 2000). While IGFBP-6 has been mainly noted for its
inhibition of IGF-II signalling, there is growing evidence for
IGF-independent actions also in the case of IGFBP-6. One
example for such actions is the induction of cancer cell
migration by IGFBP-6 (Fu et al. 2007, 2010). Recently, a
functional nuclear localization signal (NLS) was reported for
IGFBP-6, mediating its nuclear import by importin-α (Iosef
et al. 2008) in permeabilized cells, and IGFBP-6 was
identified as new interaction partner for the nuclear protein
Ku80 (Iosef et al. 2010). However, it is unclear how IGFBP-
6 can enter intact cells and, unlike in the case of the related
proteins IGFBP-3 and −5, endocytic uptake of extracellular
IGFBP-6 was not described.
Since IGFBP-6 was identified as a strong oncosuppres-
sor (see above), it may be possible to use it as a
therapeutical agent against certain tumors, as has been
demonstrated for the related protein IGFBP-3 before (Liu et
al. 2005). Since its first description, several procedures to
purify IGFBP-6 from various sources have been described.
Small amounts of hIGFBP-6 have been purified from
conditioned medium of transformed human fibroblasts by
hydrophobic interaction chromatography (HIC) and
reverse-phase HPLC (Martin et al. 1990). Alternatively,
IGF-II affinity purification followed by reverse-phase
HPLC has been utilized to purify hIGFBP6 produced by
PC-3 cells (Srinivasan et al. 1996). On a larger scale,
purification has been done from supernatants of recombi-
nant Pichia pastoris strains expressing and secreting
hIGFBP-6, using ion exchange chromatography and HIC
(Chen et al. 2007). To provide a gentle and efficient
procedure to obtain mg quantities of recombinant
hIGFBP-6 secreted from human cells, we have explored
the biosynthetic capacities of human osteosarcoma cells
(U-2OS) which were successfully used for highly efficient
ectopic production of other human proteins, including
IGFBP-3 (Pircher et al. 2010). In this communication, we
used an efficient purification procedure independent of the
IGF-II binding capacity of hIGFBP-6 to produce highly
pure IGFBP-6 protein.
Materials and methods
Cell culture
U-2OS human osteosarcoma cells were obtained from
ATCC (American Type Culture Collection, Wesel,
Germany). Human diploid fibroblasts (HDF) were iso-
lated from human foreskin of newborns (Wagner et al.
2001). U-2OS overexpressing IGFBP-6 were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) con-
taining Glutamax (Gibco Invitrogen, Lofer, Austria),
which was supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Biochrom, Berlin, Germany), 100 U/ml
penicillin with 0.1 mg/ml streptomycin (Gibco Invitrogen,
Lofer,Austria)and200μg/mlhygromycinB(BDBiosciences
Clontech, Palo Alto, CA, USA). All other cell types were
maintainedinDMEM(Sigma,Vienna,Austria),supplemented
with 10% heat-inactivated FBS, 4 mM L-glutamine (Gibco
Invitrogen, Lofer, Austria) and 100 U/ml penicillin with
0.1 mg/ml streptomycin. The cells were grown in an
atmosphere of 5% CO2 at 37°C and were subcultured by
trypsinization with 0.05% trypsin-EDTA (Gibco Invitrogen,
Lofer, Austria) every 3–4d a y s .
Generation of stable IGFBP-6 overexpressing U-2OS
clones
2 μg of pcDNA3.1/Hygro(−) plasmid containing IGFBP-6
cDNA (GenBank: NM_002178, introduced via XhoI and
HindIII restriction sites) along with 6 μl of Lipofectamine
2000 (Invitrogen, Lofer, Austria) were used for transfection
of 80% confluent U-2OS in a 35 mm dish. 4 h after
transfection, cells were washed with medium and cultivated
for additional 48 h in DMEM. Subsequently, cells were put
under selection by addition of 200 μg/ml hygromycin B
(BD Biosciences Clontech, Palo Alto, CA, USA). The
medium containing hygromycin B was replaced every
2 days until the cells reached confluency. Cells were then
re-seeded on 145 mm dishes, and 24 single, isolated cells
were picked from the dish with a sterile pipet tip and
expanded in individual wells. Cell supernatants of all
individual stable clones were tested for IGFBP-6 levels by
ELISA, and the clone showing the highest level of IGFBP-
6 expression was selected for the harvesting of conditioned
media.
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3×10
6 U-2OS cells, stably overexpressing IGFBP-6, were
seeded on 25 large (145 mm) dishes each. Two days later the
cells were washed twice with PBS, and 12.5 ml of fresh
serum-free DMEM was added to the cells. 3 days later the
medium was harvested and substituted with 12.5 ml of fresh
serum-free medium. The harvested medium was centrifuged
at 300 g, and the supernatant was frozen at −20°C.
Harvesting was repeated up to 8 times every 3 days.
Cation exchange chromatography of IGFBP-6
230 ml of harvested cell culture supernatant were supple-
mented with four protease inhibitor tablets (Complete,
Roche, Vienna, Austria) and 25 ml of 500 mM sodium
acetate, pH 4.5. After filtration through a 0.45 μm bottle-
top filter (Steritop, Millipore, Schwalbach, Germany) the
cleared supernatant was applied to a 8 ml cation exchange
column (Mono S, GE Healthcare, Vienna, Austria) attached
to an ÄKTA purifier system (GE Healthcare, Vienna,
A u s t r i a )a n dp r e v i o u s l ye q u i l i b r a t e dw i t hb u f f e rB
(50 mM sodicum acetate, 1 M NaCl, pH 4.5) followed
by buffer A (50 mM sodium acetate, 100 mM NaCl, pH
4.5). After washing with buffer A, protein bound to the
column was eluted by applying a linear 85 ml salt
gradient ranging from buffer A to buffer B and collected
in 2 ml fractions. The main peak fractions (20 ml) were
pooled and concentrated to a volume of 1–2m lu s i n ga
centrifugal filter device (Amicon Ultra, Millipore,
Schwalbach, Germany).
Hydrophobic interaction chromatography of IGFBP-6
The pool of the ion exchange purification was mixed with
10 volumes of buffer A (30% saturated ammonium sulfate
in 50 mM sodium phosphate, 100 mM NaCl, pH 7.0),
cleared by centrifugation, and applied to a 5 ml HIC
column (HiTrap Phenyl HP, GE Healthcare, Vienna,
Austria) attached to an ÄKTA purifier system (GE Health-
care, Vienna, Austria) and previously equilibrated with
buffer A. Protein bound to the column was eluted by
applying a linearly decreasing 80 ml salt gradient ranging
from buffer A to buffer B (50 mM sodium phosphate,
100 mM NaCl, pH 7.0) and collected in 2 ml fractions. The
main peak fractions (18 ml) were pooled and concentrated
to a volume of 1–2 ml using a centrifugal filter device.
Heparin affinity chromatography of IGFBP-6
The pool of the HIC purification was mixed with 10
volumes of buffer A (30 mM sodium phosphate, 50 mM
NaCl, pH 7.0), concentrated to 1–2 ml, and applied to a
1 ml Heparin column (HiTrap Heparin HP, GE Healthcare,
Vienna, Austria) attached to an ÄKTA purifier system (GE
Healthcare, Vienna, Austria) and previously equilibrated
with buffer A. Protein bound to the column was eluted by
applying a linear 30 ml salt gradient ranging from buffer A
to buffer B (30 mM sodium phosphate, 1 M NaCl, pH 7.0)
and collected in 2 ml fractions. The main peak fractions
containing IGFBP-6 (8 ml) were pooled and concentrated
to a volume of 1–2 ml using a centrifugal filter device.
Size exclusion chromatography of IGFBP-6
The pool of the heparin purification was applied to a
120 ml gel filtration column (HiLoad Superdex G75 16/60,
GE Healthcare, Vienna, Austria) attached to an ÄKTA
purifier system (GE Healthcare, Vienna, Austria) and
previously equilibrated with gel filtration buffer (50 mM
sodium phosphate, 100 mM NaCl, pH 7.0). Samples were
collected in 2 ml fractions. The main peak fractions
containing IGFBP-6 (8 ml) were pooled and concentrated
to a volume of 1–2 ml using a centrifugal filter device.
Aliquots were shock-frozen in liquid nitrogen and stored
at −80°C.
Qualitative and quantitative evaluation of purified IGFBP-6
Standard silver staining and Western blot protocols were
used to monitor the progress of the purification and perform
qualitative evaluation of the samples. For Western blot, a
mouse monoclonal antibody raised against recombinant
human IGFBP-6 (MAB8761, R&D Systems Europe,
Abingdon, UK) was used as primary antibody at a dilution
of 1:2,000 (for analysis of crude cell supernatants) to
1:40,000 (for analysis of purification steps), HRP-linked
polyclonal goat anti-mouse antibody (P0447, Dako,
Glostrup, Denmark) was used as secondary antibody.
Quantitative analysis was performed by ELISA (DuoSet
human IGFBP-6, R&D Systems Europe, Abingdon, UK)
according to the manufacturer’s protocol.
IGF ligand Western blot
450 ng of purified IGFBP-6 and 20 ng of purified IGFBP-3
(Pircher et al. 2010) were separated by SDS-PAGE,
transferred to a PVDF membrane, and probed with
biotinylated human IGF-II using an IGFBP Western-
ligand blotting kit (IBT Systems, Reutlingen, Germany)
according to the manufacturer’s protocol.
IGF-II-dependent Akt phosphorylation
HDF at passage 8 were plated at a density of 150,000 cells
per 6-well in DMEM supplemented with 10% FCS, 4 mM
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mycin. Cells were allowed to adhere for 6 h, then medium
was replaced with serum-free DMEM and cells were
starved for 24 h. Cells were treated with 350 ng/ml purified
IGFBP-6 protein in the presence or absence of 50 ng/ml
recombinant human IGF-II (Sigma, Vienna, Austria) in
serum-free DMEM for 20 min at 37°C. As a control, a
corresponding volume of buffer solution (50 mM sodium
phosphate, 100 mM NaCl, pH 7.0) was used. All
corresponding mixtures were pre-incubated for 30 min at
37°C before the experiment was initiated. After 20 min
incubation, cells were washed twice with ice-cold PBS and
harvested in a buffer containing 50 mM sodium phosphate,
150 mM NaCl, 1% Nonidet P40, 0.1% SDS, 0.5% sodium
deoxycholate, 2 mM EDTA, 10 mM NaVO3, 5 mM NaF,
and 10 mM ß-glycerophosphate (pH 7.8). The lysates were
incubated for 30 min on ice, centrifuged at 20,000 g for
15 min at 4°C, and equal protein quantities were separated
by SDS-PAGE and transferred to PVDF membranes.
Protein concentrations were determined by Bradford assay
(Wagner et al. 2001). Levels of phospho-Akt and Akt1
were assessed by Western blot using rabbit polyclonal
phospho-Akt (Ser473) antibody (Cell Signaling Technolo-
gy, Frankfurt am Main, Germany) and goat polyclonal
AKT1 (D-17) antibody (Santa Cruz Biotechnology, Heidel-
berg, Germany). Actin levels were assessed as a loading
control by rabbit monoclonal actin antibody (Epitomics,
Burlingame, CA, USA).
Labeling of purified IGFBPs with AlexaFluor 647
100 μg of purified IGFBP-6 or IGFBP-3 (Pircher et al. 2010)
protein (in 50 mM sodium phosphate, 100 mM NaCl, pH
7.0) at a concentration of 1 mg/ml were fluorescence-labeled
using AlexaFluor 647 Monoclonal Antibody Labeling Kit
(Molecular Probes Invitrogen, Lofer, Austria) according to
the manufacturer’s protocol. Briefly, IGFBP-6 or IGFBP-3
protein was incubated with AlexaFluor 647 dye for 1 h at
room temperature. Unbound dye was removed by applying
the complex to the resin column.
Endocytosis assay
For confocal live cell imaging analysis of IGFBP-6 and
IGFBP-3 uptake, U-2OS cells were plated at a density of
50,000 cells per well in the 8-well Lab-Tek Chamber Slide
System (Nalge Nunc International, Naperville, IL, USA)
and transiently transfected with 0.3 μg of pNup153-EGFP
plasmid (kindly provided by Dr. Jan Ellenberg, Heidelberg,
Germany) and 1 μl Lipofectamine 2000 (Invitrogen). On
the next day the medium was replaced, and experiments
were initiated by the addition of AlexaFluor 647-labeled
IGFBP-6 or −3 at the final concentration of 10 μg/ml in
serum-free DMEM supplemented with 4 mM L-glutamine,
100 U/ml penicillin with 0.1 mg/ml streptomycin, and
25 mM HEPES (Gibco Invitrogen, Lofer, Austria). Cells
were monitored 2 h after the addition of IGFBP-6 or −3
using the microlens-enhanced Nipkow disk-based confocal
system UltraVIEW RS (Perkin Elmer, Wellesley, MA,
USA) mounted on an Olympus IX-70 inverse microscope
(Olympus, Nagano, Japan). Images were acquired using a
100× oil immersion objective (Olympus, PlanApo, 1.4
NA). Image acquisition and analysis were performed using
the UltraVIEW RS software (Perkin Elmer, Wellesley, MA,
USA).
IGF-II cell binding assay
100,000 U-2OS cells were seeded on cover slips (15 mm
diameter) in 12-well plates in DMEM supplemented with
10% FCS. On the next day the medium was replaced by
serum-free DMEM and cells were starved for 24 h. Cells
were then incubated with 50 ng/ml of biotinylated human
IGF-II (IBT Systems, Reutlingen, Germany) in the presence
or absence of 500 ng/ml purified IGFBP-6 protein for 2 h at
4°C. Cells were washed 3× with PBS, fixed with ice-cold
methanol/acetone (1:1) fixative for 2 min at −20°C, and
dried for 30 min at RT. Cover slips were rehydrated with
PBS and incubated in blocking buffer (1% BSA in PBS) for
20 min at RT. Afterwards, cover slips were treated with
1.5 μg/ml Streptavidin-AlexaFluor 488 conjugate (Invitro-
gen, Lofer, Austria) and 1 μg/ml of nuclear marker TO-
PRO-3 (Invitrogen, Lofer, Austria) in blocking buffer. After
1 h of incubation, slides were washed with PBS and
embedded in 10 μl of DABCO mounting medium. Analysis
was performed by confocal microscopy (Zeiss Axiophot) at
40× magnification.
Results
Production of native IGFBP-6 in human osteosarcoma cells
For the production of native IGFBP-6 in its physiologically
available form, U-2OS osteosarcoma cells were stably
transfected with an expression vector, where the full-
length IGFBP-6 cDNA, including the leader peptide
sequence, was expressed from a CMV promoter construct.
The production of IGFBP-6 by 24 isolated single clones
was monitored by ELISA, and the clone with the highest
production rate was selected for further analysis. To avoid
possible complications during purification due to the
presence of serum, as observed with IGFBP-3 (Pircher et
al. 2010), IGFBP-6 expressing cells were washed and
subsequently grown in serum-free medium for 3 days. The
conditioned medium was harvested and 7 times replaced by
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staining demonstrated that contamination with serum
albumin (approx. 70 kDa) was negligible (Fig. 1a). To
monitor production of IGFBP-6 under these conditions,
supernatants were separated by gel electrophoresis and
analyzed by Western blot using IGFBP-6 antibodies.
Irrespective of serum growth factors, the cells maintained
production of IGFBP-6 in all conditioned media, peaking
during harvests 3–6 (Fig. 1b). Several O-glycosylation sites
were reported for IGFBP-6 (Neumann et al. 1998).
Accordingly, IGFBP-6 from U-2OS supernatants was found
to comprise several protein species in the molecular weight
(MW) range between 30 and 36 kDa (Fig. 1b).
Pre-purification by cation exchange and hydrophobic
interaction chromatography
Like IGFBP-3 and −5, IGFBP-6 contains a heparin-binding
consensus sequence in its C-terminal domain, albeit with an
approximately 10-fold lower binding affinity (Fowlkes et
al. 1997). Whereas we reported the purification of IGFBP-3
directly from cellular supernatants by heparin affinity
chromatography (Pircher et al. 2010), IGFBP-6 from
conditioned media did not bind to the heparin agarose
column when assayed directly (A. Taferner et al., unpub-
lished). Accordingly, a pre-purification procedure had to be
designed, taking into account the known physicochemical
properties of the protein. While the theoreticaI pI of
IGFBP-6 (lacking its leader sequence) amounts to 7.9,
mature IGFBP-6 species were found to exhibit a pI between
4.8 and 5.8 due to various posttranslational modifications
(Weber et al. 1999). We found that binding of IGFBP-6 to a
cation exchange resin was negligible at neutral pH, whereas
efficient binding was achieved at pH 4.5. Cellular super-
natants were pH adjusted by the addition of concentrated
buffer, loaded on a Mono S cation exchange column, and
eluted by a salt gradient. Starting at a salt concentration of
250 mM NaCl, a prominent peak was eluted (Fig. S1A).
When the fractions of the cation exchange chromatography
were analyzed by SDS-PAGE and silver staining (Fig. 2a),
we found the majority of IGFBP-6 protein in fractions 11–
20. The identity of the 34 kDa protein band as IGFBP-6
was confirmed by Western blot (Fig. 2b).
We determined through ammonium sulfate fractionation
that IGFBP-6 begins to precipitate above 30% ammonium
sulfate saturation (data not shown). Thus, the concentrated
pool of the cation exchange purification was adjusted to
this saturation level by addition of ammonium sulfate
buffer, and the cleared supernatant was applied to a
hydrophobic interaction chromatography (HIC) column.
Bound protein was eluted by a decreasing salt gradient,
with the main peak emerging at the very end of the gradient
Fig. 1 IGFBP-6 production and
harvest. a IGFBP-6 expressing
U-2OS cells were expanded in
DMEM containing 10% fetal
bovine serum and subsequently
grown in serum-free DMEM.
Every 3 days the supernatant
was replaced by fresh serum-
free medium and again condi-
tioned for 3 more days. The
experiment was terminated after
8 cycles of media conditioning,
and eight subsequent superna-
tants (#1 through 8) were col-
lected and analyzed by SDS-
PAGE as indicated. Subse-
quently, the gel was silver
stained. M: molecular weight
markers. b Supernatants shown
in panel a were analyzed by
Western blotting, using antibod-
ies to IGFBP-6. Supernatants
contain several IGFBP-6 forms
of slightly different MW (see
below, Fig. 4) which migrated as
a broad band in this experiment
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silver staining (Fig. 3a), and we found the majority of
IGFBP-6 in fractions 11–19. The identity of IGFBP-6 was
confirmed by Western blot (Fig. 3b).
Final purification by heparin affinity chromatography
and gel filtration
Fractions 13–21 obtained from the HIC column were salt
adjusted and loaded onto a heparin agarose affinity column.
The column was eluted with a salt gradient ranging from
50 mM to 1 M NaCl (Fig. S1C). The protein content of the
individual fractions was monitored by silver staining along
with the column input and flow-through (Fig. 4a), and
IGFBP-6 was identified by Western blot (Fig. 4b). The
apparent absence of IGFBP-6 in the flow-through con-
firmed that prior purification of IGFBP-6 allows quantita-
tive binding of the protein to the heparin column. At this
step of the purification procedure, different MW forms of
IGFBP-6 could be detected, probably reflecting differential
glycosylation, as was shown for IGFBP-3 before.
After three purification steps as described above, we
found IGFBP-6 strongly enriched from the original super-
natant. However, an unidentified band with an apparent
MW of 25 kDa that was not recognized by IGFBP-6
antibodies still remained as a notable impurity (Fig. 4b). To
remove this major contaminant, fractions 4–7 of the heparin
purification pool were concentrated and subjected to size
exclusion chromatography on a gel filtration column (Fig.
S1D). Input, flow-through, and individual fractions were
analyzed by SDS-PAGE, silver staining (Fig. 5a), and
Western blot (Fig. 5b). Fractions 14–17 of the gel filtration
Fig. 2 IGFBP-6 purification by cation exchange chromatography. a
Selected fractions obtained by Mono S chromatography were
separated by SDS-PAGE along with molecular weight markers (M),
column input (IN), and column flow-through (FT), as indicated. The
gel was silver stained. The positions of IGFBP-6 protein species as
deduced from comparison with Western blot analysis (see below,
panel b) are indicated. n.s. marks a non-specific band representing a
protein of approx. 25 kDa that is not recognized by IGFBP-6
antibodies. b Fractions derived from Mono S purification were
separated by SDS-PAGE as shown in panel a, transferred to a PVDF
membrane, and probed with antibodies to IGFBP-6 using Western
blot. Designation of lanes is as in panel a. Please note that for this and
the following Western blots, the IGFBP-6 antibodies were diluted
1:40,000, to allow clean identification of IGFBP-6 in highly enriched
fractions (e.g. fraction 17). For this reason, the column input is not
visible here. The input signal is well visible at higher antibody
concentrations, e.g. after dilution 1:2,000 (see Fig. 1b)
282 A. Taferner et al.were found to not contain the non-specific band and
subsequently pooled.
To assess the degree of purification and the yield of the
chromatography procedure shown here, the progressive
steps of the IGFBP-6 purification were analyzed on a silver
stained gel (Fig. 6) and subjected to ELISA quantification,
respectively. This experiment reveals a strong enrichment
of IGFBP-6, along with a considerable purification, since
all visible impurities have been eliminated by the purifica-
tion procedure. We found that 230 ml of conditioned
medium contained roughly 2 mg of IGFBP-6 (Table 1), and
the protein concentration was augmented from 7.9 μg/ml
(in the original input) to approx. 1 mg/ml (in the
concentrate of the final fractions). The final concentrated
pool derived from the G75 size exclusion chromatography
still contained about 1 mg of IGFBP-6, indicating a yield of
roughly 50% (Table 1).
Inhibition of IGF signal transduction by purified IGFBP-6
To test the intactness of IGFBP-6 obtained by the
purification procedure described here, we performed an
IGF Western-ligand blot, demonstrating the ability to bind
human IGF-II (Fig. 7a). We also tested the ability of
IGFBP-6 to sequester IGF-II and thereby block signaling
through the IGF receptor signal transduction pathway.
Human diploid fibroblasts were serum starved for 24 h.
Cells were then left untreated or treated with IGF-II for
20 min. IGF receptor dependent signal transduction was
monitored by analyzing the phosphorylation of Akt, a
major readout of IGF-II signalling (Foulstone et al. 2005).
Addition of IGF-II led to a significant increase in Akt
phosphorylation with no significant change in the abun-
dance of the Akt protein (Fig. 7b). Addition of IGFBP-6 at
a concentration of 350 ng/ml led to a complete and specific
downregulation of Akt phosphorylation (Fig. 7b), suggest-
ing that IGFBP-6 after recombinant expression in mamma-
lian cells and purification by four-step chromatography
retained biological activity.
As further proof of functionality, we tested the ability of
purified IGFBP-6 to block binding of IGF-II to the cell
surface. Serum-starved U-2OS cells were treated with
biotinylated IGF-II in presence or absence of purified
IGFBP-6. Incubation was done at 4°C to inhibit endocyto-
sis. Staining with a Streptavidin fluorescence marker
demonstrated that accumluation of IGF-II at the cell surface
is strongly reduced in presence of IGFBP-6 (Fig. 8).
IGFBP-6 is not internalized by human osteosarcoma cells
To assess potential cellular uptake of IGFBP-6 by endocy-
tosis, IGFBP-6 was labeled by AlexaFluor 647 and added
Fig. 3 IGFBP-6 purification by
hydrophobic interaction chro-
matography. a Selected fractions
from the hydrophobic interac-
tion column were separated by
SDS-PAGE along with molecu-
lar weight markers (M), column
input (IN), and column flow-
through (FT), as indicated. The
gel was silver stained. The
positions of IGFBP-6 protein
species as defined by Western
blot (see below, panel b) are
indicated. n.s. depicts a non-
specific protein of approx.
25 kDa that is not recognized by
IGFBP-6 antibodies. b Fractions
of the hydrophobic interaction
column were separated by SDS-
PAGE as shown in panel a,
transferred to a PVDF mem-
brane, and probed with antibod-
ies to IGFBP-6 using Western
blot. Designation of lanes is as
in panel a
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GFP fusion protein (pNup153-EGFP) used here to visualize
the nuclear envelope (Rabut et al. 2004). Purified IGFBP-3
(Pircher et al. 2010) was labeled in the same way und used
as a control. While fluorescent labeled IGFBP-3 was
readily internalized after 2 h, accumulating in vesicular
structures, no uptake was observed for IGFBP-6 within this
time frame (Fig. 9).
Discussion
We describe here a new procedure for the recombinant
production and subsequent purification to apparent homo-
geneity of IGF-binding protein-6. This was achieved by
four subsequent chromatographic steps, which resulted in
highly pure protein with acceptable yield (approx. 50%).
We also established that IGFBP-6 prepared by this
procedure retained its biological activity. Moreover, we
provide data that cellular uptake of IGFBP-6 is restricted
with respect to other proteins such as IGFBP-3.
A new protocol for purification of native human IGFBP-6
In this communication, we have established a new protocol
for the production and purification of recombinant human
IGFBP-6 in a human cell type. Higher expression levels
and yields of IGFBP-6 would be achievable in bacteria or
primitive eukaryotes, thereby simplifying purification. For
example, purification of recombinant hIGFBP-6 from
Pichia pastoris has been reported to yield approx. 60 mg/
liter culture medium (Chen et al. 2007). However,
expression in human cells ensures authentic post-
translational modification and processing of hIGFBP-6,
which may prove important for biological studies and
potential therapeutic use. Small differences in apparent
molecular weight were reported when comparing hIGFBP-
6 purifications from different sources (Chen et al. 2007;
Martin et al. 1990), which suggest differences in post-
translational modifications, of unknown significance. For
these reasons, we prefer the production of recombinant
protein in conditioned media of human cell lines. By
utilizing a U-2OS based expression system driven by a
Fig. 4 IGFBP-6 purification by
heparin affinity chromatography.
a Selected fractions from the
heparin agarose column were
separated by SDS-PAGE along
with molecular weight markers
(M), column input (IN), and
column flow-through (FT), as
indicated. The gel was silver
stained. b Fractions of the hep-
arin column were separated by
SDS-PAGE as shown in panel a,
transferred to a PVDF mem-
brane, and probed with antibod-
ies to IGFBP-6 using Western
blot. Designation of lanes is as
in panel a. Please note that
elution from the heparin affinity
column reveals several distinct
forms of IGFBP-6, probably
differing in the extent of glyco-
sylation, similar to previous
findings with IGFBP-3 (Pircher
et al. 2010)
284 A. Taferner et al.CMV promoter construct, we achieved IGFBP-6 concentra-
tions of up to 10 mg/liter of cellular supernatant. We avoided
possible complications due to the presence of serum proteins,
as observed for the purification of IGFBP-3 (Pircher et al.
2010), by growing the cells in serum-free medium.
While purification of IGFBP-6 by IGF-II affinity
chromatography, followed by reverse-phase HPLC, has
been reported (Srinivasan et al. 1996), we opted against this
strategy, thus allowing the future use of our protocol for the
purification of IGFBP-6 mutants lacking IGF-II binding
activity. IGFBP-6 has been successfully purified as a His6-
tagged protein (Headey et al. 2004), but we wanted to avoid
the possible drawbacks related to the use of a tagged
protein, and concentrated instead on the physicochemical
properties as well as the heparin binding affinity of IGFBP-
6. Strong enrichment of IGFBP-6 from the cellular
supernatant proved to be necessary before quantitative
binding to a heparin column could be achieved, apparently
due to the 10-fold lower heparin affinity in comparison to
other IGFBPs (Fowlkes et al. 1997). We achieved this
enrichment by a pre-purification protocol, combining ion
exchange and hydrophobic interaction chromatography,
leading to the removal of the majority of contaminants.
After successful heparin affinity chromatography, one
significant contaminant, representing an unknown protein
species of ca. 25 kDa apparent molecular weight, remained.
Fig. 5 IGFBP-6 purification by
size exclusion chromatography.
a Selected fractions from the gel
filtration column were separated
by SDS-PAGE along with mo-
lecular weight markers (M) and
column input (IN), as
indicated. The gel was silver
stained. b Fractions of the gel
filtration column were separated
by SDS-PAGE as shown in
panel a, transferred to a PVDF
membrane, and probed with
antibodies to IGFBP-6 using
Western blot. Designation of
lanes is as in panel a
Fig. 6 Analysis of IGFBP-6 purity. Aliquots of the cellular
supernatant, the pooled Mono S fractions, the pooled HIC fractions,
the pooled heparin fractions, and the pooled gel filtration fractions
were analyzed by SDS-PAGE, as indicated, followed by silver
staining. Most visible contaminants, in particular the prominent
contaminating protein of approx. 25 kDa (nonspecific: n.s.), have
been removed during the purification
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IGFBP-6, as was reported to occur during the purification
of hIGFBP-6 from Pichia pastoris (Chen et al. 2007),
however, the band was not recognized by IGFBP-6
antibodies in Western blot. Whereas this observation may
reflect the absence of the epitope recognized by the
antibodies, this was not further investigated. Successful
removal of this contaminant was achieved by size exclusion
chromatography as a final purification step.
Functional characterization of native human IGFBP-6
IGF binding proteins play an important role in modulating
the proliferative effects of IGFs and are the subject of
increasing investigation (Hwa et al. 1999). Moreover, there
is now solid evidence suggesting that some of the IGFBPs,
including IGFBP-6, have biological activity that is inde-
pendent of their effect on the IGF pathway (Fu et al. 2010).
IGF-independent functions were also linked to intracellular
IGFBP-6 and its nuclear uptake (Iosef et al. 2010).
The major advantage of the procedure described here is
the possibility to produce high amounts of native and
biologically active IGFBP-6 from human cell supernatants,
which can be used for a variety of biological assays. This is
demonstrated in the functional experiments, where we
found that 350 ng/ml of IGFBP-6 completely blocked Akt
phosphorylation induced by IGF-II. Although it is known
that IGFBP-6 interacts with IGF-II with about 50-fold
higher affinity compared to IGF-I, still the interaction of
IGFBP-3, known to interact primarily with IGF-I, with
IGF-II was much higher compared to IGFBP-6, at least in
Western ligand blotting shown here. The limited sensitivity
of Western ligand blotting for the identification of IGFBP-6
has been noted in earlier studies (Srinivasan et al. 1996). As
Table 1 Overview of IGFBP-6 purification
Sample Volume IGFBP-6 conc. IGFBP-6 total
Mono S Input 255 ml 7.93 μg/ml 2,022 μg
Mono S Pool 8.60 ml 0.186 mg/ml 1,600 μg
HIC Pool 1.49 ml 0.788 mg/ml 1,174 μg
Heparin Pool 0.75 ml 1.388 mg/ml 1,041 μg
Gel Filtration Pool 0.97 ml 1.024 mg/ml 993 μg
For each of the chromatographic steps, the volume of the pooled IGFBP-6 containing fractions is indicated. IGFBP-6 concentration in each pool
was determined by ELISA, and the total yield of IGFBP-6 was calculated for each step
Fig. 7 Functional analysis of purified IGFBP-6. a 450 ng of purified
IGFBP-6 and 20 ng of purified IGFBP-3 were separated by SDS-
PAGE as indicated, transferred to a PVDF membrane, and probed with
biotinylated human IGF-II using an IGFBP Western-ligand blotting
kit. Protein species binding to biotinylated IGF-II are indicated in each
case. b Diploid human fibroblasts were serum starved for 24 h and
then incubated with 50 ng/ml of IGF-II or left untreated, as indicated.
Where indicated, 350 ng/ml IGFBP-6 was added. Cellular extracts
were prepared and probed with antibodies to Akt, phospho-Akt, and
actin, as indicated. The data suggest that IGFBP-6 abrogates IGF
receptor dependent signal transduction pathway
286 A. Taferner et al.further proof for the inhibition of IGF signal transduction
by purified IGFBP-6, we demonstrated that IGFBP-6
blocks the ability of IGF-II to bind to the cell surface of
U-2OS osteosarcoma cells. In accordance to existing data,
like IGFBP-6 species analyzed from human cerebrospinal
fluid (Weber et al. 1999), results reported here suggest that
upon purification, in particular during heparin affinity
chromatography, different isoforms of IGFBP-6 with
slightly different MW, probably reflecting differential
glycosylation, can be separated.
We also used the IGFBP-6 produced by our new
purification method to study its potential uptake by U-2OS
cells. In contrast to IGFBP-3, which is readily internalized by
these cells,no short-termuptakeofIGFBP-6 was observed by
us.RecentstudieshaveshownthatcellularuptakeofIGFBP-3
and −5 fusion proteins can be inhibited by addition of
heparin (Goda et al. 2008), indicating that endocytosis of
these proteins is mediated by interaction with cell surface-
bound heparin. Taking into account the significantly
reduced heparin affinity of IGFBP-6 in comparison to
other members of the IGFBP protein family (Fowlkes et
al. 1997), this may explain the lack of IGFBP-6 internal-
ization in our experiments. The intracellular, and in
particular the nuclear, mode of action of IGF binding
proteins has been the subject of ongoing debate in the
field, and the current view is that prototypical IGFBP
family members, such as IGFBP-3, are internalized by
endocytosis before they reach the nucleus (Lee et al.
2004), although the uptake route from endosomes to the
nucleus has not been fully elucidated. Our finding
Fig. 8 Study of influence of
IGFBP-6 on IGF-II cell bind-
ing. Serum-starved U-2OS cells
were left untreated or incubated
with biotinylated IGF-II in
presence or absence of purified
IGFBP-6 at 4°C. After washing
and fixation, cells were treated
with Streptavidin-AlexaFluor
488 for detection of IGF-II
(green fluorescence) and nuclear
marker TO-PRO-3 (red fluores-
cence) and analyzed by confocal
microscopy. Representative
images are shown. Bar, 20 μm
Fig. 9 Study of cellular IGFBP-6 uptake by live cell imaging. U-2OS
cells were transiently transfected with an expression vector for
nucleoporin153 fused with GFP (green fluorescence). 24 h after
transfection, cells were analyzed by confocal live cell microscopy in
the absence of labeled IGFBPs (CTR) and 2 h after the addition of
AlexaFluor 647-labeled IGFBP-6 or IGFBP-3 (red fluorescence).
Representative confocal images are shown. Bar, 5 μm
Purification and characterization of native human IGFBP-6 287reported here that IGFBP-6 is a poor substrate for the
endocytic apparatus adds another piece to this puzzle. It
seems that, at least in the case of IGFBP-6, other models
of IGFBPs’ nuclear actions not involving secretion and
reuptake of IGFBP-6 prior to its nuclear import, e.g. a
model implying “intracrine mechanisms” (Butt et al.
2003), will have to be reconsidered.
Of note, IGFBP-6 has been shown to act as an
oncosuppressor in certain cancer cells; consequently, the
application of recombinant IGFBP-6 has been suggested as
a new therapeutic strategy of such malignancies (Kuo et al.
2010). This may stimulate interest to use recombinant
IGFBP-6 protein as a potential therapeutic agent, as was
previously demonstrated for IGFBP-3 (Liu et al. 2005).
Recombinant human IGFBP-6 in high purity and produced
from human cells would be required for this purpose.
Whereas we describe here a procedure suitable for the
purification of rhIGFBP-6 in laboratory scale, additional
experiments for upscaling will be required to achieve this
goal.
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